Yes, the patents running till 2021 will probably not keep a generic Zyvox off the market. Teva is challenging the '792 patent that runs until Nov. 18, 2014 (May 18, 2015 including the pediatric extension). Pfizer filed suit against Teva early this year, in the U.S. District Court for the District of Delaware asserting the infringement of the basic patent, asking for an injunction. See here: http://patentdocs.typepad.com/files/pfizer-v-teva-2.pdf I'm not following Trius but took a look and torezolid' efficacy (the 200mg dose from phase II in cSSSI/MRSA trial) does look better in comparison with data from Zyvox on clinical cure rates in the CE, ME and ITT groups, and seems to have a few advantages over Zyvox. In addition to those you've mentioned there's also the possibility for longer course (whereas Zyvox carries an irreversible occular toxicity risk when dosed more than 4 weeks and reversible thrombocytopenia when taken more than 2 weeks. It also has an increased rate of death with Gram-negative infections, so that's another angle in which TSRX may be able to differentiate torezolid in the future).
News 
Market Data 
Discover 
